These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21279949)
21. Complications of total implantable access ports and efficacy of Taurolidine-citrate lock solution against catheter-related infections. Ince E; Oğuzkurt P; Temiz A; Ezer SS; Gezer HÖ; Yazici N; Hiçsönmez A Afr J Paediatr Surg; 2014; 11(2):138-42. PubMed ID: 24841014 [TBL] [Abstract][Full Text] [Related]
22. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. Filiopoulos V; Hadjiyannakos D; Koutis I; Trompouki S; Micha T; Lazarou D; Vlassopoulos D Am J Nephrol; 2011; 33(3):260-8. PubMed ID: 21372561 [TBL] [Abstract][Full Text] [Related]
23. Taurolidine lock is highly effective in preventing catheter-related bloodstream infections in patients on home parenteral nutrition: a heparin-controlled prospective trial. Bisseling TM; Willems MC; Versleijen MW; Hendriks JC; Vissers RK; Wanten GJ Clin Nutr; 2010 Aug; 29(4):464-8. PubMed ID: 20061070 [TBL] [Abstract][Full Text] [Related]
24. Taurolidine lock solution for catheter-related bloodstream infections in pediatric patients: A meta-analysis. Sun Y; Wan G; Liang L PLoS One; 2020; 15(4):e0231110. PubMed ID: 32255798 [TBL] [Abstract][Full Text] [Related]
25. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Betjes MG; van Agteren M Nephrol Dial Transplant; 2004 Jun; 19(6):1546-51. PubMed ID: 14993498 [TBL] [Abstract][Full Text] [Related]
26. Taurolidine lock - experience from the West of Scotland. Cullis PS; McKee RF Clin Nutr; 2011 Jun; 30(3):399-400; author reply 401. PubMed ID: 21256637 [No Abstract] [Full Text] [Related]
27. Taurolidine-Citrate Line Locks Prevent Recurrent Central Line-Associated Bloodstream Infection in Pediatric Patients. Clark JE; Graham N; Kleidon T; Ullman A Pediatr Infect Dis J; 2019 Jan; 38(1):e16-e18. PubMed ID: 30204661 [TBL] [Abstract][Full Text] [Related]
28. Clinical and economic impact of the taurolidine lock on home parenteral nutrition. Arnoriaga Rodríguez M; Pérez de Ciriza Cordeu M; Camblor Álvarez M; Bretón Lesmes I; Motilla de la Cámara M; Velasco Gimeno C; Arhip L; García Peris P; Cuerda Compés C Nutr Hosp; 2018 Jun; 35(4):761-766. PubMed ID: 30070861 [TBL] [Abstract][Full Text] [Related]
29. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Solomon LR; Cheesbrough JS; Ebah L; Al-Sayed T; Heap M; Millband N; Waterhouse D; Mitra S; Curry A; Saxena R; Bhat R; Schulz M; Diggle P Am J Kidney Dis; 2010 Jun; 55(6):1060-8. PubMed ID: 20207458 [TBL] [Abstract][Full Text] [Related]
30. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. Wouters Y; Theilla M; Singer P; Tribler S; Jeppesen PB; Pironi L; Vinter-Jensen L; Rasmussen HH; Rahman F; Wanten GJA Aliment Pharmacol Ther; 2018 Aug; 48(4):410-422. PubMed ID: 29978597 [TBL] [Abstract][Full Text] [Related]
31. A 2% taurolidine catheter lock solution prevents catheter-related bloodstream infection (CRBSI) and catheter dysfunction in hemodialysis patients. Neusser MA; Bobe I; Hammermeister A; Wittmann U Br J Nurs; 2021 Jul; 30(14):S24-S32. PubMed ID: 34288746 [TBL] [Abstract][Full Text] [Related]
32. [Taurolidine for the prevention of catheter-related infections in children with intestinal insufficiency: preliminary experience in a Chilean tertiary hospital]. Jordán P M; Haro C; Puchi A Rev Chilena Infectol; 2021 Feb; 38(1):15-21. PubMed ID: 33844787 [TBL] [Abstract][Full Text] [Related]
33. Taurolidine and catheter-related bloodstream infection: a systematic review of the literature. Bradshaw JH; Puntis JW J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):179-86. PubMed ID: 18664870 [TBL] [Abstract][Full Text] [Related]
34. Taurolidine/Citrate Lock Therapy for Primary Prevention of Catheter-Related Infections in Cancer Patients: Results of a Prospective, Randomized, Phase IV Trial (ATAPAC). Longo R; Llorens M; Goetz C; Platini C; Eid N; Sellies J; Ouamara N; Quétin P Oncology; 2017; 93(2):99-105. PubMed ID: 28463827 [TBL] [Abstract][Full Text] [Related]
35. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. Dümichen MJ; Seeger K; Lode HN; Kühl JS; Ebell W; Degenhardt P; Singer M; Geffers C; Querfeld U J Hosp Infect; 2012 Apr; 80(4):304-9. PubMed ID: 22342714 [TBL] [Abstract][Full Text] [Related]
36. Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections. Jurewitsch B; Jeejeebhoy KN Clin Nutr; 2005 Jun; 24(3):462-5. PubMed ID: 15896434 [TBL] [Abstract][Full Text] [Related]
37. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin. Handrup MM; Møller JK; Schrøder H Pediatr Blood Cancer; 2013 Aug; 60(8):1292-8. PubMed ID: 23417891 [TBL] [Abstract][Full Text] [Related]
38. Taurolidine lock is superior to heparin lock in the prevention of catheter related bloodstream infections and occlusions. Olthof ED; Versleijen MW; Huisman-de Waal G; Feuth T; Kievit W; Wanten GJ PLoS One; 2014; 9(11):e111216. PubMed ID: 25379781 [TBL] [Abstract][Full Text] [Related]